Trial Profile
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Gadopentetic acid
- Indications Renal cancer
- Focus Therapeutic Use
- 15 Jun 2012 Actual patient number is 18 according to ClinicalTrials.gov.
- 15 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 15 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.